Cochrane · systematic review · CD010292
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
Welsch, P, Üçeyler, N, Klose, P, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySerotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design
Population: people with fibromyalgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported pain relief of 50% or greater Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.09 [0.07, 0.11] | 15 studies · 6918 participants | Low Downgraded: indirectness, publication bias |
Patient Global Impression to be much or very much improved (PGIC) Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.19 [0.12, 0.26] | 6 studies · 2918 participants | Low Downgraded: indirectness, publication bias |
Self‐reported fatigue (20‐100 scale) Higher scores indicate higher fatigue problem levels Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 12 studies · 6168 participants | Low Downgraded: indirectness, publication bias |
Self‐reported sleep problems (0‐100 scale) Higher scores indicate higher sleep problem levels Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 8 studies · 4547 participants | Low Downgraded: indirectness, publication bias |
Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 14 studies · 6861 participants | Low Downgraded: indirectness, publication bias |
Tolerability (withdrawal due to adverse events) Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.07 [0.04, 0.1] | 15 studies · 7029 participants | Low Downgraded: indirectness, publication bias |
Safety (serious adverse events) Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 13 studies · 6732 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Serotonin and noradrenaline reuptake inhibitors (SNRI) versus placebo for fibromyalgia syndrome (FMS) ‐ results at final treatment
Population: Participants with FMS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain (0‐100 scale) Higher scores indicate higher pain levels Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | no estimate extracted | 10 studies · 6038 participants | High |
50% pain reduction Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | RR 1.49 [1.35, 1.64] | 10 studies · 5994 participants | High |
Fatigue (20‐100 scale) Higher scores indicate higher fatigue levels Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | no estimate extracted | 9 studies · 5656 participants | High |
Sleep problems (0‐100 scale) Higher scores indicate higher sleep problem levels Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | no estimate extracted | 6 studies · 4081 participants | Low Downgraded: imprecision |
Disease‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | no estimate extracted | 10 studies · 5987 participants | High |
Withdrawal due to adverse events Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | RR 1.83 [1.53, 2.18] | 10 studies · 6179 participants | High |
Serious adverse events Serotonin and noradrenaline reuptake inhibitors (SNRI) vs placebo | RR 0.78 [0.55, 1.12] | 9 studies · 5845 participants | Moderate Downgraded: imprecision |